Près De La Bannière
Section Gratuite  - Video Lectures

07. Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention

Publié sur 1 février 2026 Certification date d'expiration: 1 février 2029

Robert Hudak, M.D.

Professor of Psychiatry - University of Pittsburgh

Points Clés

  • Consider second-generation antipsychotics as a third-line augmentation option for OCD treatment. Of these, only aripiprazole, risperidone, olanzapine, and quetiapine have sufficient evidence.
  • When using SGA for OCD, aripiprazole is recommended due to its similar response rates to risperidone while having fewer side effects. Additionally, it has not been shown to worsen OCD symptoms.
  • Use lower SGA doses for OCD augmentation than for bipolar disorder or psychosis. Response typically appears within 4-6 weeks; consider discontinuing if no significant improvement after a two-month trial.

Gratuit Téléchargements pour un Accès Hors ligne

  • Gratuit Télécharger le Fichier PDF
  • Gratuit Télécharger Fichier Audio (MP3)
  • Gratuit Télécharger la Vidéo (format MP4)

Diapositives et transcription

Diapositive 1 sur 14

The Role of Second-Generation Antipsychotics in OCD Treatment.
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 1 sur 14

Diapositive 2 sur 14

So note that with the second-generation antipsychotics, I consider them to be third-line augmentation only. I will often see patients who are started on second-generation antipsychotics as they are started on SSRIs. Various reasons are given for that by the prescribing clinicians, and I will tell you that there is no evidence that second-generation antipsychotics have any benefit at all early on in OCD treatment. So it’s not recommended.
Références :
  • Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive–compulsive disorder: A systematic review and meta-analysis. BMC Psychiatry, 14, 317. https://doi.org/10.1186/s12888-014-0317-5
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 2 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

Diapositive 3 sur 14

The response for a second-generation antipsychotic for OCD augmentation is usually seen in four to six weeks. I give my patients a two-month trial, and if they don’t get significant improvement, I pull the second-generation antipsychotic. Note that if patients have schizotypal-type symptoms, so odd beliefs that are associated with the OCD or if they have delusional level of insight, antipsychotics are not recommended.
Références :
  • Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive–compulsive disorder: A systematic review and meta-analysis. BMC Psychiatry, 14, 317. https://doi.org/10.1186/s12888-014-0317-5
  • Borue, X., Sharma, M., & Hudak, R. (2015). Biological treatments for obsessive-compulsive and related disorders. Journal of Obsessive-Compulsive and Related Disorders, 6, 7-26. https://doi.org/10.1016/j.jocrd.2015.03.003
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 3 sur 14

Diapositive 4 sur 14

With second-generation, notice that patients with tics may have an improved response over other OCD patients, but there are no specific characteristics of the OCD itself that have been identified that relate to response of second-generation antipsychotics. So once you diagnose someone with OCD, it doesn’t matter what type of OCD symptoms that they have, we don’t know of any medication treatment that’s tailored to fit actual OCD subtypes or symptoms.
Références :
  • Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M. B., & Leckman, J. F. (2006). A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry, 11(7), 622–632. https://doi.org/10.1038/sj.mp.4001823
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 4 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

Diapositive 5 sur 14

Now, be aware that second-generation antipsychotics are not a homogenous group of medication. You just don’t prescribe any second-generation antipsychotic for OCD willy-nilly. These are very different groups of medications. And the doses we use for the SGAs are much less than the one we use for bipolar disorder or psychosis.
Références :
  • Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive–compulsive disorder: A systematic review and meta-analysis. BMC Psychiatry, 14, 317. https://doi.org/10.1186/s12888-014-0317-5
  • Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M. B., & Leckman, J. F. (2006). A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry, 11(7), 622–632. https://doi.org/10.1038/sj.mp.4001823
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 5 sur 14

Diapositive 6 sur 14

Now, I note that the second-generation antipsychotics may worsen OCD as well as augment. There had been numerous case reports of SGAs worsening OCD. So you do have to be careful with that. It has been reported with clozapine, in particular clozapine quite often makes OCD much worse. Olanzapine, risperidone, and quetiapine have also been reported to have worsening of OCD symptoms as well as augmenting OCD symptoms. They are less studied in children.
Références :
  • Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive–compulsive disorder: A systematic review and meta-analysis. BMC Psychiatry, 14, 317. https://doi.org/10.1186/s12888-014-0317-5
  • Bleakley, S., Brown, D., & Taylor, D. (2011). Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review. Therapeutic Advances in Psychopharmacology, 1(6), 181-188. https://doi.org/10.1177/2045125311425971
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 6 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

Diapositive 7 sur 14

And note that if you do have someone on a second-generation antipsychotic, they require biannual or yearly blood sugar, lipid profile and AIMS test. So you need to do the monitoring appropriately with people on second-generation antipsychotics.
Références :
  • Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive–compulsive disorder: A systematic review and meta-analysis. BMC Psychiatry, 14, 317. https://doi.org/10.1186/s12888-014-0317-5
  • Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M. B., & Leckman, J. F. (2006). A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry, 11(7), 622–632. https://doi.org/10.1038/sj.mp.4001823
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 7 sur 14

Diapositive 8 sur 14

So in the order of recommendation, I typically recommend aripiprazole as my top line second-generation antipsychotic. It did show to work with a double-blind randomized controlled trial. The response rates were similar to risperidone. While it doesn’t have quite as much evidence of risperidone, it does have less side effects. The usual dose is about 2 to 15 mg, and note that it’s the only one of the recommended antipsychotics that has not been shown to worsen OCD symptoms.
Références :
  • Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 18(9), pyv047. https://doi.org/10.1093/ijnp/pyv047
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 8 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

Diapositive 9 sur 14

Risperidone is the one SGA that has the most evidence as an augmenter. It has a double-blind randomized controlled trial. And the usual dose is 0.5 to 2 mg a day.
Références :
  • Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 18(9), pyv047. https://doi.org/10.1093/ijnp/pyv047
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 9 sur 14

Diapositive 10 sur 14

Olanzapine has some double-blind, randomized controlled trials, not nearly as much as the others. It may also worsen OCD and so you need to be very careful with olanzapine. Usual dose is 2.5 to 15 mg a day.
Références :
  • Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 18(9), pyv047. https://doi.org/10.1093/ijnp/pyv047
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 10 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

Diapositive 11 sur 14

Quetiapine seems to have less data than the others, and its data tend to be both positive and negative. Usually low dose at 50 to 200 mg daily. Now, the other second-generation antipsychotics have very little data. Therefore, I do not recommend any of the other second-generation antipsychotics.
Références :
  • Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 18(9), pyv047. https://doi.org/10.1093/ijnp/pyv047
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 11 sur 14

Diapositive 12 sur 14

And see this graph here. What they did was that they took two groups of patients who were considered treatment-resistant OCD. They gave one ERP; they gave the second risperidone. And they found out that the response to risperidone was minimal. The response to adding ERP was pretty robust. So the take-home point from this is that appropriate and expertly performed ERP is more powerful even than risperidone augmentation. So again, always ensure that your patients are in appropriate ERP treatment. And ERP augmentation is going to be much more powerful than any other medication augmentation that we can do.
Références :
  • Foa, E. B., Simpson, H. B., Rosenfield, D., Liebowitz, M. R., Cahill, S. P., Huppert, J. D., Bender, J., Jr, McLean, C. P., Maher, M. J., Campeas, R., Hahn, C. G., Imms, P., Pinto, A., Powers, M. B., Rodriguez, C. I., Van Meter, P. E., Vermes, D., & Williams, M. T. (2015). Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 76(4), 440–446. https://doi.org/10.4088/JCP.14m09044
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 12 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

Diapositive 13 sur 14

So the key points for this. Second-generation antipsychotics are generally considered a third- or fourth-line augmentation strategy when weighing risks and benefits. Only four second generation antipsychotics have been studied enough to recommend – risperidone, aripiprazole, olanzapine and quetiapine.
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 13 sur 14

Diapositive 14 sur 14

All of these medications have been reported to exacerbate OCD as well and clozapine does in particular can exacerbate it, with the exception of aripiprazole. Second-generation antipsychotics require close monitoring and despite their efficacy as augmentation, they may even be less effective than just simply behavioral therapy.
Antipsychotiques de deuxième génération pour l’augmentation de l’OCD : Agents de troisième intention Diapositive 14 sur 14
Gratuit Fichiers

Télécharger le PDF et autres fichiers

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.

La Section Suivante

08. Autres agents d’augmentation pour l’OCD : buspirone, ondansétron et options émergentes

Gagner des crédits pour votre apprentissage!

Réclamer 1.25 CME

CME de l'Information

Learning Objectives:
After completing this activity, the learner will be able to:
1. Apply DSM-5 diagnostic criteria to accurately identify OCD and distinguish obsessions from psychotic symptoms, avoiding common misdiagnoses that contribute to treatment resistance.
2. Implement evidence-based pharmacotherapy for OCD, including proper SSRI dosing (at or above FDA maximums), defining adequate therapeutic trials.
3. Evaluate treatment-resistant OCD cases to distinguish inadequate treatment from true treatment resistance, and determine appropriate timing for advanced interventions.

Original Release Date: February 01, 2026
Expiration Date: February 01, 2029

Faculty: Robert Hudak, M.D.
Medical Editor: Tomás Abudarham, M.D.

Relevant Financial Disclosures:
None of the faculty, planners, and reviewers for this educational activity has relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-prod.psychopharmacologyinstitute.com

Instructions for Participation and Credit:
Participants must complete the activity online within the valid credit period noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.
  2. Complete the Post-Activity Evaluation to provide the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
  3. Download your certificate.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Medical Academy designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Artificial Intelligence (AI) Use Disclosure
Artificial intelligence (AI) tools may have been used in limited stages of developing this activity (e.g., drafting or language refinement). The specific tool, version, and date of use are documented internally.
AI does not determine clinical recommendations. All content is reviewed, verified, and approved by the listed faculty and medical editors, and reflects independent human clinical judgment consistent with ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Gratuit Fichiers

Téléchargements gratuits pour l'Accès Hors connexion

Succès!
Vérifiez votre boîte de réception, nous vous avons envoyé tous les matériaux.
Continuer sur le site
Fenêtre d’accès instantané

Devenir un Bronze, Silver, Gold, Bronze extended, Silver extended, Gold extended, Bronze – fr, Bronze extended – fr, Silver – fr, Silver extended – fr, Gold – fr ou Gold extended – fr Membre.

Programme CME de psychopharmacologie 2025–26

Débloquez jusqu’à 155 crédits CME, dont 40 crédits CME SA.

Obtenez L'Accès Instantané
Ou vous identifier si vous avez un compte
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.